Who are Cozaar®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Irbesartan Oral Tablet, Allisartan Isoproxil, Irbesartan (Aprovel), potassium losartan, losartan (drug), Low dose losartan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cozaar.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Cozaar® — Competitive Intelligence Brief

Cozaar® (Cozaar®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB). Area: Cardiovascular.

marketed Angiotensin II receptor blocker (ARB) AT1 receptor (angiotensin II type 1 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Cozaar® (Cozaar®) — Teva Pharmaceuticals USA. Cozaar blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Cozaar® TARGET	Cozaar®	Teva Pharmaceuticals USA	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Irbesartan Oral Tablet	Irbesartan Oral Tablet	University of Southern Denmark	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Allisartan Isoproxil	Allisartan Isoproxil	Guangdong Provincial People's Hospital	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Irbesartan (Aprovel)	Irbesartan (Aprovel)	Sanofi	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
potassium losartan	potassium losartan	Fifth Affiliated Hospital, Sun Yat-Sen University	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
losartan (drug)	losartan (drug)	Odense University Hospital	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Low dose losartan	Low dose losartan	Baker Heart and Diabetes Institute	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) class)

Chong Kun Dang Pharmaceutical · 2 drugs in this class
Baker Heart and Diabetes Institute · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Lee's Pharmaceutical Limited · 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
Guangdong Provincial People's Hospital · 1 drug in this class
Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
Bayer · 1 drug in this class
Arbor Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cozaar® — Competitive Intelligence Brief. https://druglandscape.com/ci/cozaar. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab